IgG4 Disease: Treatment Advances & Monitoring Strategies – Healio Rheumatology

The landscape of IgG4-related disease (IgG4-RD) management is becoming clearer, with emerging data solidifying the roles of glucocorticoids and B-cell targeted therapies. While still a relatively rare and often misunderstood systemic fibroinflammatory disorder, advancements in understanding its complexities are offering hope for more effective treatment strategies. A recent discussion at the Basic and Clinical Immunology for the Busy Clinician symposium highlighted these key approaches, emphasizing the importance of early recognition and ongoing monitoring.

Understanding IgG4-RD: A Complex Condition

IgG4-RD is characterized by its ability to affect multiple organs, often presenting insidiously – meaning symptoms develop gradually and can be easily overlooked. Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology and professor of medicine at the Cleveland Clinic Lerner College of Medicine, described it as a “protean condition” capable of manifesting in various ways. Landmark data on B-cell depletion have offered renewed hope for patients, but significant challenges remain in both diagnosis and long-term management.

Accurate diagnosis is a crucial first step, but can be demanding. Calabrese stressed that relying solely on imaging or pathology is insufficient. The disease can present in different phenotypes – such as Mikulicz disease (affecting salivary and lacrimal glands), pancreato-biliary involvement, or retroperitoneal fibrosis – or even in atypical, organ-limited forms. This variability underscores the need for a comprehensive diagnostic approach.

The Cornerstone of Treatment: Glucocorticoids and B-Cell Targeting

Currently, glucocorticoids remain the primary treatment for IgG4-RD. Calabrese noted that they are “our friends in this condition,” often proving effective in controlling inflammation. A typical starting dose of 0.6 mg/kg/day is often sufficient, avoiding the need for high-dose regimens in most cases. Yet, glucocorticoids are not a cure and long-term use carries potential side effects, making the search for alternative and complementary therapies essential.

This is where B-cell targeted therapies come into play. Research has increasingly focused on B cells as key drivers of the immune dysregulation seen in IgG4-RD. The only therapy currently approved for IgG4-RD is inebilizumab (Uplizna, Amgen), which has demonstrated high efficacy in clinical trials.

While rituximab (Rituxan, Genentech) – an older B-cell depleting agent – has been widely used “extensively” in treating IgG4-RD, it currently lacks formal FDA approval for this indication. Calabrese explained that while rituximab has proven effective, the absence of a randomized controlled trial supporting its use limits its official status.

Emerging Therapies and the Future of IgG4-RD Management

The pipeline for IgG4-RD treatment is expanding, with several promising new agents under investigation. Bruton tyrosine kinase (BTK) inhibitors are currently in phase 3 trials, offering a potential oral treatment option. Another promising agent is obexelimab (Zenas BioPharma), which inhibits B-cell populations without causing complete depletion – a potentially less disruptive approach.

Looking further ahead, Calabrese suggested that CAR T-cell therapy, while still investigational in IgG4-RD, may have a role in extreme cases. Rheumatologists are viewing CAR T-cell therapy as revolutionary, but cost and safety concerns temper enthusiasm.

Monitoring and Long-Term Management

Regardless of the treatment approach, ongoing monitoring is critical for patients with IgG4-RD. Regular physical examinations (every 4 months) and laboratory tests – including IgG4 levels, immunologic parameters, and organ-specific markers (liver function tests, creatinine, urine protein/creatine ratio) – are essential. Serial imaging should also be considered, tailored to the individual patient’s presentation.

The primary goal of treatment is to prevent fibrosis, the scarring of tissues that can lead to organ damage. Calabrese emphasized the importance of intervening at the proliferative stage of the disease, before irreversible fibrosis develops.

What to Expect in the Coming Years

The field of IgG4-RD is rapidly evolving. Continued research is needed to better understand the disease’s underlying mechanisms, identify biomarkers for early diagnosis and treatment response, and develop more targeted therapies. Clinicians are urged to remain vigilant, keeping IgG4-RD in the differential diagnosis for patients presenting with unexplained organ involvement. As Calabrese noted, “We are all in a learning phase with this… We have to keep it in our differential diagnosis. Once we have diagnosed these patients, they all deserve lifelong monitoring.”

For more information:

Leonard H. Calabrese, DO, can be reached at [email protected].